VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
+5.59%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$169M
AUM Growth
-$13M
(-7.2%)
Cap. Flow
-$16.1M
Cap. Flow
% of AUM
-9.55%
Top 10 Holdings %
Top 10 Hldgs %
6.26%
Holding
495
New
55
Increased
122
Reduced
257
Closed
60
Top Buys
| 1 |
NVIDIA
NVDA
|
$1.21M |
| 2 |
Netflix
NFLX
|
$1.05M |
| 3 |
Meta Platforms (Facebook)
META
|
$1.04M |
| 4 |
Adobe
ADBE
|
$995K |
| 5 |
Applied Materials
AMAT
|
$977K |
Top Sells
| 1 |
ATVI
Activision Blizzard Inc.
ATVI
|
$1.01M |
| 2 |
Progressive
PGR
|
$999K |
| 3 |
Stryker
SYK
|
$984K |
| 4 |
Republic Services
RSG
|
$973K |
| 5 |
Linde
LIN
|
$966K |
Sector Composition
| 1 | Healthcare | 27.98% |
| 2 | Technology | 15.96% |
| 3 | Financials | 11.34% |
| 4 | Energy | 8.43% |
| 5 | Industrials | 8.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
426
Recursion Pharmaceuticals
RXRX
$2.01B
| $82.4K | 0.05% |
11,028
-57
| -0.5% | -$426 |
|
427
Pliant Therapeutics
PLRX
$114M
| $81K | 0.05% |
4,469
-810
| -15% | -$14.7K |
|
428
Terns Pharmaceuticals
TERN
$632M
| $80.8K | 0.05% |
+9,239
| New | +$80.8K |
|
429
Editas Medicine
EDIT
$248M
| $80.7K | 0.05% |
9,805
+36
| +0.4% | +$296 |
|
430
Viking Therapeutics
VKTX
$3.03B
| $78.7K | 0.05% |
+4,857
| New | +$78.7K |
|
431
uniQure
QURE
$985M
| $64.3K | 0.04% |
5,611
+1,305
| +30% | +$15K |
|
432
Biomea Fusion
BMEA
$114M
| $61.4K | 0.04% |
+2,795
| New | +$61.4K |
|
433
Mersana Therapeutics
MRSN
$34M
| $37.5K | 0.02% |
455
-112
| -20% | -$9.22K |
|
434
BioXcel Therapeutics
BTAI
$55.2M
| $34K | 0.02% |
319
-12
| -4% | -$1.28K |
|
435
FibroGen
FGEN
$48.9M
| $17.9K | 0.01% |
265
-3
| -1% | -$203 |
|
436
Repare Therapeutics
RPTX
$72.6M
| – | – |
-6,808
| Closed | -$67K |
|
437
Adicet Bio
ACET
$60M
| – | – |
-9,506
| Closed | -$54.8K |
|
438
Archer Daniels Midland
ADM
$30.2B
| – | – |
-10,521
| Closed | -$838K |
|
439
Aflac
AFL
$57.2B
| – | – |
-12,406
| Closed | -$800K |
|
|
AFMD
440
DELISTED
Affimed
AFMD
| – | – |
-8,575
| Closed | -$63.9K |
|
441
Altimmune
ALT
$334M
| – | – |
-9,389
| Closed | -$39.6K |
|
442
Atara Biotherapeutics
ATRA
$90.7M
| – | – |
-1,043
| Closed | -$75.6K |
|
443
Brown & Brown
BRO
$31.3B
| – | – |
-14,323
| Closed | -$822K |
|
444
C4 Therapeutics
CCCC
$194M
| – | – |
-12,350
| Closed | -$38.8K |
|
445
CDW
CDW
$22.2B
| – | – |
-4,438
| Closed | -$865K |
|
446
Codexis
CDXS
$218M
| – | – |
-18,136
| Closed | -$75.1K |
|
447
Church & Dwight Co
CHD
$23.3B
| – | – |
-10,639
| Closed | -$941K |
|
448
Check Point Software Technologies
CHKP
$20.7B
| – | – |
-6,877
| Closed | -$894K |
|
449
Centene
CNC
$14.2B
| – | – |
-11,709
| Closed | -$740K |
|
450
CSX Corp
CSX
$60.6B
| – | – |
-27,690
| Closed | -$829K |
|